ClinicalTrials.gg
TerminatedNCT03870451Updated Oct 13, 2026Results posted

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

An interventional study of VascuTherm5 vascular compression device in Chemotherapy-induced Peripheral Neuropathy and Plasma Cell Myeloma, sponsored by Wake Forest University Health Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Device feasibility

How we know

Why this study was terminated
Low accruals
Updated Oct 13, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences — 5 open to participants now, 7 under way, none of them phase 3. Multiple Myeloma · Wake Forest University Health Sciences.

Enrollment
9th of 17
18 · median 18
Started
2019
with 1 other
No phase
5 of 24
none open now
Registered
14th of 24
by date

Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 with no phase, and was the 14th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

5 of the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the feasibility of daily cryocompression therapy in multiple myeloma patients with bortezomib-induced peripheral neuropathy (BIPN).

SECONDARY OBJECTIVES:

I. To examine the change in patient-reported assessment of neuropathy based on the sensory, motor and autonomic neuropathy scores on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Cancer-Induced Peripheral Neuropathy (CIPN20) (patient-reported outcome [PRO]) from baseline to 4 and 8 weeks after the start of cryocompression therapy.

II. To examine the change in physician graded assessment of peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 criteria from baseline to 4 and 8 weeks after the start of cryocompression therapy.

III. To assess the effect on sensory and motor nerve function via nerve conduction study (NCS) (e.g. conduction velocity, latency, and amplitude) and neuro-ultrasound after 8 weeks of daily cryocompression therapy.

EXPLORATORY OBJECTIVES:

I. To explore the effect of 8 weeks of cryocompression on changes in digital artery perfusion as measured by ultrasound (US).

II. To examine the associations among the peripheral nerve assessment measures (nerve conduction and peripheral nerve US) with the patient reported outcomes (EORTC QLQ-CIPN20, PRO-CTCAE) at baseline, week 4, week 8, and for the change from baseline to week 8.

OUTLINE:

Patients undergo home cryocompression therapy treatments on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

After completion of cryocompression therapy, patients are followed up at 30 days.

03

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy
  • Plasma Cell Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed multiple myeloma (any International Staging System [ISS] stage).
  • Clinical symptoms of bortezomib-induced peripheral neuropathy as measured by the .

Cohort 1: Patients with clinically documented CTCAE grade greater than or equal 2 neuropathy.

Cohort 2: Patients with clinically documented CTCAE grade 1-2 neuropathy.

  • Currently or previously received bortezomib-containing regimen

Cohort 1: Patients who have previously received a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.

Cohort 2: Patients who are currently receiving a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.

  • Age must be greater than or equal to 18 years.
  • (ECOG) =\< 4.
  • >= 6 months.
  • Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved document.

Exclusion criteria

Exclusion Criteria:

  • Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of bortezomib therapy.
  • Other explanatory etiology for neuropathy.
  • Presumptive evidence of congestive heart failure.
  • Current deep vein thrombosis or pulmonary embolism (diagnosed within the past 6 months).
  • Current pulmonary edema.
  • Unable to provide accurate medical history.
  • Pregnant women are excluded from this study because they will not be receiving myeloma standard of care (SOC) therapy or bortezomib-based therapy per inclusion criteria.
  • Current or previously documented inflammatory phlebitis; thrombophlebitis; decompensated cardiac insufficiency; arterial dysregulation; erysipelas; carcinoma or carcinoma in the affected extremity; decompensated hypotonia; venous or arterial occlusive disease; or Raynaud's disease;
  • Current monoclonal gammopathy of undetermined significance (MGUS), Waldenstroms macroglobulinemia, or Castleman disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1 VascuTherm5 vascular compression device

    VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

    Device: VascuTherm5 vascular compression device

  • Experimental
    Cohort 2 VascuTherm5 vascular compression device

    VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

    Device: VascuTherm5 vascular compression device

Interventions

  • DeviceVascuTherm5 vascular compression device

    VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device

06

What researchers measure

Primary outcomes

  1. Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments

    The primary outcome measure will be feasibility of daily 30-minute cryocompression treatments with a target of 60% compliance. Compliance will be measured with patient diaries. Only periods for which diaries exist will be evaluated. Compliance is defined as completion of 60% of prescribed treatment days. Completion of at least 25 of 30 minutes on each day will be considered completion of therapy on the prescribed day. Analyses will be primarily descriptive to estimate variances and effect sizes for future work. The proportion of compliance and its 95% confidence interval will be calculated for each cohort.

    Time frame: Baseline up to 8 weeks of cryocompression therapy

Secondary outcomes

  1. EORTC QLQ-CIPN20 Questionnaire

    Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. Patient-reported assessment of neuropathy based on 19 questions from components of sensory, motor, and autonomic neuropathic. Question responses are (scale of 1 to 4) 1 being "not at all" and 4 being "very much." The total EORTC score (calculated as the average of the component responses) (range 1-4) and then converted to a 100 point scale (range 0-100) with higher scores having more severe symptoms or greater functional limitation. EORTC QLQ-CIPN20 (PRO) will be done at baseline, and at 4 and 8 weeks of cryocompression therapy.

    Time frame: Baseline, 4 weeks, 8 weeks

  2. NCI-CTCAE v5.0 Severity Grade Changes

    Physician graded assessment of peripheral neuropathy as measured by NCI-CTCAE v5.0 criteria. The CTCAE displays Grades 1 through 5 (1 = mild, 5 = death)

    Time frame: Baseline, 4 weeks, 8 weeks

  3. Change in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 Weeks

    Change in tibial motor response from baseline to 8 weeks will include tibial amplitude (mV)

    Time frame: Baseline, 8 weeks

  4. Change in Motor Nerve Function (Latency) From Baseline to 8 Weeks

    Change in Tibial motor response from baseline to 8 weeks will include latency (ms)

    Time frame: Baseline, 8 weeks

  5. Change in Motor Nerve Function (Conduction Velocity) From Baseline to 8 Weeks

    Change in tibial motor response from baseline to 8 weeks will include conduction velocity (m/sec).

    Time frame: Baseline, 8 weeks

  6. Sensory Response Evaluability at Baseline and 8 Weeks

    Sural sensory response (collected as yes/no) measured on both the left and right ankles at baseline and 8 weeks for amplitude, onset latency, and peak latency. Reported are the number with sural sensory response measured (yes).

    Time frame: Baseline, 8 weeks

07

Results

Posted Oct 13, 2026
Limitations and caveats
The primary outcome was evaluated using only patient diaries that were returned. Patient diaries themselves have a tendency to be unreliable and by excluding those that are not returned from the calculations the results could be biased toward better completion.

Participant flow

Participant flow — Overall Study
MilestoneGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Started126
Completed95
Not completed31
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up01

Outcome measures

PrimaryFeasibility - Ability to Complete Daily 30-minute Cryocompression Treatments

The primary outcome measure will be feasibility of daily 30-minute cryocompression treatments with a target of 60% compliance. Compliance will be measured with patient diaries. Only periods for which diaries exist will be evaluated. Compliance is defined as completion of 60% of prescribed treatment days. Completion of at least 25 of 30 minutes on each day will be considered completion of therapy on the prescribed day. Analyses will be primarily descriptive to estimate variances and effect sizes for future work. The proportion of compliance and its 95% confidence interval will be calculated for each cohort.

Time frame:
Baseline up to 8 weeks of cryocompression therapy
Reported as:
Number · percentage of compliant participants
Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments
percentage of compliant participantsGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments100 (100 to 100)66.7 (4.3 to 77.7)
SecondaryEORTC QLQ-CIPN20 Questionnaire

Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. Patient-reported assessment of neuropathy based on 19 questions from components of sensory, motor, and autonomic neuropathic. Question responses are (scale of 1 to 4) 1 being "not at all" and 4 being "very much." The total EORTC score (calculated as the average of the component responses) (range 1-4) and then converted to a 100 point scale (range 0-100) with higher scores having more severe symptoms or greater functional limitation. EORTC QLQ-CIPN20 (PRO) will be done at baseline, and at 4 and 8 weeks of cryocompression therapy.

Time frame:
Baseline, 4 weeks, 8 weeks
Reported as:
Mean · score on a scale
EORTC QLQ-CIPN20 Questionnaire
score on a scaleGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Baseline39 ± 1730 ± 8
4 weeks27 ± 1125 ± 12
8 weeks28 ± 1522 ± 7
SecondaryNCI-CTCAE v5.0 Severity Grade Changes

Physician graded assessment of peripheral neuropathy as measured by NCI-CTCAE v5.0 criteria. The CTCAE displays Grades 1 through 5 (1 = mild, 5 = death)

Time frame:
Baseline, 4 weeks, 8 weeks
Reported as:
Number · participants
NCI-CTCAE v5.0 Severity Grade Changes
participantsGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Baseline - Grade 1 Peripheral Neuropathy11
Baseline - Grade 2 Peripheral Neuropathy85
Baseline - Grade 3 Peripheral Neuropathy30
Week 4 - Grade 1 Peripheral Neuropathy10
Week 4 - Grade 2 Peripheral Neuropathy75
Week 4 - Grade 3 Peripheral Neuropathy00
Week 8 - Grade 1 Peripheral Neuropathy22
Week 8 - Grade 2 Peripheral Neuropathy54
Week 8 - Grade 3 Peripheral Neuropathy30
SecondaryChange in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 Weeks

Change in tibial motor response from baseline to 8 weeks will include tibial amplitude (mV)

Time frame:
Baseline, 8 weeks
Reported as:
Mean · mV
Change in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 Weeks
mVGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Right Median Wrist-0.6 ± 2.31.0 ± 1.9
Left Median Wrist-0.2 ± 2.6-0.5 ± 2.1
Right Median Elbow-0.8 ± 2.01.0 ± 2.1
Left Median Elbow0 ± 2.0-0.1 ± 1.6
Right Tibial Ankle0.4 ± 1.4-1.0 ± 1.7
Left Tibial Ankle0.8 ± 1.0-0.3 ± 2.1
SecondaryChange in Motor Nerve Function (Latency) From Baseline to 8 Weeks

Change in Tibial motor response from baseline to 8 weeks will include latency (ms)

Time frame:
Baseline, 8 weeks
Reported as:
Mean · ms
Change in Motor Nerve Function (Latency) From Baseline to 8 Weeks
msGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Right Median Wrist0.1 ± 0.40.0 ± 0.2
Left Median Wrist0.1 ± 0.3-0.1 ± 0.3
Right Median Elbow0.1 ± 0.40.0 ± 0.4
Left Median Elbow0.0 ± 0.5-0.1 ± 0.4
Right Tibial Ankle-0.1 ± 0.50.1 ± 0.3
Left Tibial Ankle0.3 ± 0.5-0.1 ± 0.2
SecondaryChange in Motor Nerve Function (Conduction Velocity) From Baseline to 8 Weeks

Change in tibial motor response from baseline to 8 weeks will include conduction velocity (m/sec).

Time frame:
Baseline, 8 weeks
Reported as:
Mean · m/s
Change in Motor Nerve Function (Conduction Velocity) From Baseline to 8 Weeks
m/sGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Right Median Elbow0.2 ± 2.8-1.0 ± 1.3
Left Median Elbow0.2 ± 4.0-0.3 ± 3.0
SecondarySensory Response Evaluability at Baseline and 8 Weeks

Sural sensory response (collected as yes/no) measured on both the left and right ankles at baseline and 8 weeks for amplitude, onset latency, and peak latency. Reported are the number with sural sensory response measured (yes).

Time frame:
Baseline, 8 weeks
Reported as:
Number · number patients
Sensory Response Evaluability at Baseline and 8 Weeks
number patientsGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
Baseline - Amplitude response - Right Sural ANKLE (Calf)22
Baseline - Amplitude response - Left Sural ANKLE (Calf)12
8 weeks - Amplitude response - Right Sural ANKLE (Calf)22
8 Weeks - Amplitude response - Left Sural ANKLE (Calf)13
Baseline - Onset Latency response - Right Sural ANKLE (Calf)22
Baseline - Onset Latency response - Left Sural ANKLE (Calf)12
8 weeks - Onset Latency response - Right Sural ANKLE (Calf)22
8 weeks - Onset Latency response - Left Sural ANKLE (Calf)13
Baseline - Peak Latency response - Right Sural ANKLE (Calf)22
Baseline - Peak Latency response - Left Sural ANKLE (Calf)12
8 weeks - Peak Latency response - Right Sural ANKLE (Calf)22
8 weeks - Peak Latency response - Left Sural ANKLE (Calf)13

Adverse events

Collected over Adverse events were collected at initiation of treatment (day 0, week 1), at week 4, and week 8 visits. One enrolled participant was never treated and no adverse event data was collected on that participant, but that participant was followed for all cause mortality.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Grade 2-3 Established Neuropathy0/12 (0%)0/11 (0%)9/11 (81.8%)
Grade 1-2 New-onset Neuropathy0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventGrade 2-3 Established NeuropathyGrade 1-2 New-onset Neuropathy
ParesthesiaNervous system disorders6/111/6
Peripheral sensory neuropathyNervous system disorders5/111/6
PainGeneral disorders3/110/6
Pain in extremityMusculoskeletal and connective tissue disorders3/111/6
ArthritisMusculoskeletal and connective tissue disorders2/110/6
Muscle crampMusculoskeletal and connective tissue disorders2/111/6
DysesthesiaNervous system disorders2/110/6
InsomniaPsychiatric disorders1/110/6
PruritusSkin and subcutaneous tissue disorders1/110/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Grade 2-3 Established NeuropathyGrade 1-2 New-onset NeuropathyTotal
<=18 years000
Between 18 and 65 years448
>=65 years8210
Sex: Female, Male
Sex: Female, Male(Participants)Grade 2-3 Established NeuropathyGrade 1-2 New-onset NeuropathyTotal
Female527
Male7411
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Grade 2-3 Established NeuropathyGrade 1-2 New-onset NeuropathyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White9514
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Grade 2-3 Established NeuropathyGrade 1-2 New-onset NeuropathyTotal
United States12618
08

Study locations

1 site
  • Wake Forest Baptist Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Feb 2023, 39 months.

Results were first posted in Oct 2026, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2019
First posted
Mar 12, 2019
StartActual
Nov 1, 2019
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Results first posted
Oct 13, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFeasibility - Ability to complete dailyComplete Daily 30-minute cryocompression treatmentsCryocompression TreatmentsTime frame: Baseline up to 8 weeks of cryocompression therapy
Oct 13, 2026
Documents
Secondary outcomes
1 edited, 2 time frame changed, 3 added, 3 removed, 1 description edited
What changed in the outcomes
  • EditedChange in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 WeeksTime frame: Baseline and after 8 weeks of cryocompression therapy → Baseline, 8 weeks
  • AddedChange in Motor Nerve Function (Latency) From Baseline to 8 WeeksTime frame: Baseline, 8 weeks
  • AddedChange in Motor Nerve Function (Conduction Velocity) From Baseline to 8 WeeksTime frame: Baseline, 8 weeks
  • AddedSensory Response Evaluability at Baseline and 8 WeeksTime frame: Baseline, 8 weeks
  • RemovedChange in Sensory ResponseTime frame: Baseline and after 8 weeks of cryocompression therapy
  • Time frameEORTC QLQ-CIPN20 QuestionnaireBaseline up to 8 weeks of cryocompression therapy → Baseline, 4 weeks, 8 weeks
  • Time frameNCI-CTCAE v5.0 Severity Grade ChangesBaseline up to 8 weeks of cryocompression therapy → Baseline, 4 weeks, 8 weeks
  • DescriptionEORTC QLQ-CIPN20 Questionnaire: how it is measured was reworded
  • Removedother outcomeVelocity changes of digital artery perfusionTime frame: Baseline and after 8 weeks of cryocompression therapy
  • Removedother outcomeProportion of Changes in Peripheral Nerve FunctionTime frame: Baseline up to 8 weeks of cryocompression therapy
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFeasibility - Ability to complete dailyComplete Daily 30-minute cryocompression treatmentsCryocompression TreatmentsTime frame: Baseline up to 8 weeks of cryocompression therapy
    Secondary outcomes 1 edited, 2 time frame changed, 3 added, 3 removed, 1 description edited
    What changed in the outcomes
    • EditedChange in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 WeeksTime frame: Baseline and after 8 weeks of cryocompression therapy → Baseline, 8 weeks
    • AddedChange in Motor Nerve Function (Latency) From Baseline to 8 WeeksTime frame: Baseline, 8 weeks
    • AddedChange in Motor Nerve Function (Conduction Velocity) From Baseline to 8 WeeksTime frame: Baseline, 8 weeks
    • AddedSensory Response Evaluability at Baseline and 8 WeeksTime frame: Baseline, 8 weeks
    • RemovedChange in Sensory ResponseTime frame: Baseline and after 8 weeks of cryocompression therapy
    • Time frameEORTC QLQ-CIPN20 QuestionnaireBaseline up to 8 weeks of cryocompression therapy → Baseline, 4 weeks, 8 weeks
    • Time frameNCI-CTCAE v5.0 Severity Grade ChangesBaseline up to 8 weeks of cryocompression therapy → Baseline, 4 weeks, 8 weeks
    • DescriptionEORTC QLQ-CIPN20 Questionnaire: how it is measured was reworded
    • Removedother outcomeVelocity changes of digital artery perfusionTime frame: Baseline and after 8 weeks of cryocompression therapy
    • Removedother outcomeProportion of Changes in Peripheral Nerve FunctionTime frame: Baseline up to 8 weeks of cryocompression therapy
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03870451
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Nov 1, 2019
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Results posted
Oct 13, 2026
Last update
Oct 13, 2026

Study contacts

Roy Strowd, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion